drugset / Trial / NCT05960955
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.
Timeline
- Start
- 2023-11-13
- Primary completion
- 2024-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK117 | Monoclonal antibody | — | Intravenous |
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | S-1 | Small molecule | — | Oral |
| Subject | fluorouracil | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |